You are here

Nanobiomedicine
Share

Nanobiomedicine


Editors-in Chief
Prof. Winston Kuo Predicine Holdings Ltd, USA
Editors-in-Chief
Dr. Markus Dettenhofer CEITEC, Czech Republic


eISSN: 18495435 | ISSN: 18495435 | Current volume: 3

Nanobiomedicine is an international, peer-reviewed, open access scientific journal that publishes research in nanotechnology as it interfaces with fundamental studies in biology, as well as its application to the fields of medicine. Nanobiomedicine covers all key aspects of this research field, including, but not limited to, bioengineering, biophysics, physical and biological chemistry, and physiology, as well as nanotechnological applications in diagnostics, therapeutic application, preventive medicine, drug delivery, and monitoring of human disease. Additionally, theoretical and modeling studies covering the nanobiomedicine fields will be considered.

Publication in the journal is subject to a one-time article processing charge (APC). The APC serves to support the journal and ensures that your article will be freely available online in perpetuity under a Creative Commons license. For an introductory period SAGE will cover all costs whilst the journal is established.

For general information on Open Access at SAGE and Open Access FAQs, please visit this page.

Submissions should be made online at http://mc.manuscriptcentral.com/nanobiomedicine.

This journal is a member of the Committee on Publication Ethics (COPE)

Nanobiomedicine is an international, peer-reviewed, open access scientific journal that publishes research in nanotechnology as it interfaces with fundamental studies in biology, as well as its application to the fields of medicine. Nanobiomedicine covers all key aspects of this research field, including, but not limited to, bioengineering, biophysics, physical and biological chemistry, and physiology, as well as nanotechnological applications in diagnostics, therapeutic application, preventive medicine, drug delivery, and monitoring of human disease. Additionally, theoretical and modeling studies covering the nanobiomedicine fields will be considered.

All submitted articles considered suitable for Nanobiomedicine are subjected to rigorous peer review to ensure the highest levels of quality. The review process is carried out as quickly as possible to minimize any delays in the online publication of articles.

Submissions are encouraged on all topics related to nanobiomedicine, and its clinical applications including but not limited to:

  • Nanoscale-structured biomaterials
  • Nanoscale bio-devices
  • Nanoscale imaging
  • Nanoscale drug delivery
  • Nanobiotechnology
  • Nanorobotics
  • Nanotoxicology
  • Nanoparticles
  • Nanocarriers
  • Nanofluidics
  • Nanosensors (nanowires, nanophotonics)
  • Nanosurgery (dermatology, gastroenterology, ophthalmology, etc)
  • Nanocarriers commercialization of nanobiomedical technologies
  • Market trends in the nanobiomedicine space
  • Ethics and regulatory aspects of nanobiomedicine approval
  • New perspectives of nanobiomedicine in clinical diagnostics
  • BioMEMS
  • Nano-coatings
  • Plasmonics
  • Nanoscale visualization
Associate Editors
Dr. Peter Burkhard University of Connecticut, United States, USA
Dr. Thomas Ming Swi Chang Artificial Cells & Organs Research Centre, McGill University, Canada
Dr. Yong Chen Ecole normale superieure, France
Dr. Utkan Demirci Stanford School of Medicine, United States, USA
Dr. Toshio Fukuda Nagoya University, Japan
Dr Zhenghong Gao University of Michigan, USA
Dr. Umut Gurkan Case Western Reserve University, United States, USA
Dr. Hossam Haick Isreal Institute of Technology, Israel
Dr. Karsten König Saarland University, Germany
Dr. Steven Little University of Pittsburgh, United States, USA
Dr. Marko Loncar Harvard University, United States, USA
Prof. Ian Nicholls Linnaeus University, Sweden
Dr. Martin Pumera Nanyang Technological University, Singapore
Dr. Alexander Seifalian University College London, UK
Dr. Molly Shoichet Univeristy of Toronto, Canada
Dr. Brian Thrall Pacific Northwest National Laboratory, United States, USA
Editorial Board Member
Dr. Demir Akin Standford University, United States
Dr. Omar Ali Harvard University, United States, USA
Dr. Kirk Andriano Elute Inc, United States, USA
Dr. Giuseppe Bardi Istituto Italiano di Tecnologia, Italy
Dr. Bharat Bhushan The Ohio State University, United States, USA
Dr. Adriano Cavalcanti Center for Automation in Nanobiotech, Australia
Dr. Adam Curtis Universty of Glasgow, UK
Dr. Hicham Fenniri Northeastern University, United States, USA
Dr. Xiaohu Gao University of Washington, United States, USA
Dr. Peixuan Guo The Ohio State University, United States, USA
Dr. Kutay Icoz Abdullah Gül Üniversitesi, Turkey
Dr. Esmaiel Jabbari University of South Carolina, United States, USA
Dr. Ali Khademhosseini Harvard Medical School, United States, USA
Dr. Vipuil Kishore Florida Institute of Technology, United States, USA
Dr. Seda Kizilel Koc University, Turkey
Dr. Alexander Lazarev Pressure BioSciences, United States, USA
Dr. Didier Letourneur Inserm U 1148, France
Dr. Allen Nicholson Temple University, United States, USA
Dr. Hyungyu Park Korea Advanced Institute of Science & Technology, Korea, Republic Of, South Korea
Dr. Steffen Petersen Aalborg University, Denmark
Dr. Pier Paolo Pompa Italian Institute of Technology, Italy
Dr. Hao Qi University of Tokyo, Japan
Dr. Fabiana Quaglia University of Naples Federico II, Italy
Dr. Qimin Quan Rowland Institute at Harvard University, United States, USA
Dr. Francesca Re University of Milano Bicocca, Italy
Dr. Angel Sacido Hospital de Madrid Foundation, Spain
Dr. Giacinto Scoles University of Udine, Italy
Dr. Shiladitya Sengupta Brigham and Women's Hospital, United States, USA
Dr. Barbara Smith Arizona State University, United States, USA
Dr. Yu Sun University of Toronto, Canada
Dr. Weihong Tan University of Florida, United States, USA
Dr. Suresh Valiyaveettil National Univeristy of Singapore, Singapore
Dr. Frank Vollmer Max Planck Institute for the Science of Light, Germany
Dr. Shuqi Wang Stanford University, United States, USA
Dr. Zhongcong Xie Massachusetts General Hospital, United States, USA
Dr. Feng Xu Xi'an Jiaotong University, China
Dr. Xiaohui Zhang Chinese Academy of Science, China
Dr. Pinar Zorlutuna University of Notre Dame, United States, USA
  • Directory of Open Access Journals (DOAJ)
  • PubMed Central (PMC)
  •  Manuscript Submission Guidelines: Nanobiomedicine

    1. Open Access
    2. Article processing charge (APC)
    3. Article Types
    4. Editorial policies
      4.1 Peer Review Policy
      4.2 Authorship
      4.3 Acknowledgements
      4.4 Funding
      4.5 Declaration of conflicting interests
      4.6 Research ethics and patient consent
      4.7 Clinical Trials
      4.8 Reporting guidelines
    5. Publishing policies
      5.1 Publication ethics
      5.2 Contributor's publishing agreement
    6. Preparing your manuscript
      6.1 Word processing formats
      6.2 Artwork, figures and other graphics
      6.3 Supplementary material
      6.4 Reference style
      6.5 English language editing services
    7. Submitting your manuscript
      7.1 ORCID
      7.2 Information required for completing your submission
      7.3 Corresponding author contact details
      7.4 Permissions
    8. On acceptance and publication
      8.1 SAGE Production
      8.2 Continuous publication
      8.3 Promoting your article
    9. Further information

    This Journal is a member of the Committee on Publication Ethics.

    Please read the guidelines below then visit the journal’s submission site http://mc.manuscriptcentral.com/Nanobiomedicine to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.

    Only manuscripts of sufficient quality that meet the aims and scope of Nanobiomedicine will be reviewed.

    As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.

    1. Open Access

    Nanobiomedicine is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.

    For general information on open access at SAGE please visit the Open Access page or view our Open Access FAQs.

    Back to top

    2. Article processing charge (APC)

    There will be no article processing charge (APC) for a limited time while the journal is being established. SAGE will cover all costs. In the future, it is expected that an APC will be charged as part of a plan for ensuring sustainability of the journal.

    Back to top

    3. Article types

    Original Research Article
    Article that presents original research work, reporting the results of one or more empirical studies or experiments.

    Short Communication
    These articles are original communications of 1 to 4 pages in length. The scope of these articles is to disseminate authors' perspectives and brief observations that do not fit full length papers, but that represent new achievements in the field to be developed in detail and reported thoroughly elsewhere.

    Invited Feature Article
    Article intended to provide readers with in-depth analysis and discussion around new advances, usually commissioned from an expert in the field.

    Perspective
    Perspectives present an opinion, hypothesis, or historical account related to nanotechnology and biomedical research, ranging from translational and clinical applications that address diagnosis, delivery of therapeutics, drug delivery and monitoring of human diseases. Prospective authors are strongly encouraged to submit a pre-submission inquiry to the Editors-in-Chief that describes the topic and scope of the proposed perspective.

    Invited Review Article
    Solicited by the Editors-in-Chief, Invited Review Articles should present an overview of the most recent advances in a given research area, including current debates and ideas of the area’s future direction. Prospective authors must submit a pre-submission inquiry to the Editors-in-Chief, describing the topic and scope of the proposed review, which the Editors-in-Chief may choose to either invite or decline.

    Conference Report
    Articles written for and presented at an academic conference. If your article is based on a conference paper that may have been published elsewhere, please ensure that the new article differs substantially from the conference paper or presentation it is based upon. Differences should be described in detail in the Cover Letter accompanying the submission, and the Acknowledgments section of the manuscript should include the following statement:

    "'This article is a revised and expanded version of a paper entitled [title] presented at [name, location and date of conference]."

    Original Research Articles should be 4 to 12 pages in length, including references, whereas other article types may be shorter.

    Back to top

    4. Editorial policies

    4.1 Peer review policy

    Following a preliminary triage to eliminate submissions unsuitable for Nanobiomedicine all papers are sent out for review. The covering letter is important. To help the Editor in his preliminary evaluation, please indicate why you think the paper suitable for publication. If your paper should be considered for fast-track publication, please explain why. The journal’s policy is to have manuscripts reviewed by two expert reviewers. Nanobiomedicine utilizes a double-blind peer review process in which the reviewer and author’s names and information are withheld from the other. All manuscripts are reviewed as rapidly as possible, while maintaining rigor. Reviewers make comments to the author and recommendations to the Editors-in-Chief who then makes the final decision.

    As part of the submission process you will be asked to provide the names of 2 peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below: 

      • The reviewer should have no prior knowledge of your submission
      • The reviewer should not have recently collaborated with any of the authors
      • Reviewer nominees from the same institution as any of the authors are not permitted

    You will also be asked to nominate peers who you do not wish to review your manuscript (opposed reviewers).

    Please note that the Editors are not obliged to invite any recommended/opposed reviewers to assess your manuscript.

    The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.

    4.2 Authorship

    Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.

    The list of authors should include all those who can legitimately claim authorship. This is all those who:

      1. Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
      2. Drafted the article or revised it critically for important intellectual content,
      3. Approved the version to be published,
      4. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

    Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.

    4.3 Acknowledgements

    All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

    4.3.1 Writing assistance

    Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance”).

    It is not necessary to disclose use of language polishing services.

    Please supply any personal acknowledgements separately to the main text to facilitate anonymous peer review.

    4.4 Funding

    Nanobiomedicine requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. 

    4.5 Declaration of conflicting interests

    It is the policy of Nanobiomedicine to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.

    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.

    For guidance on conflict of interest statements, please see the ICMJE recommendations.

    4.6 Research ethics and patient consent

    Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

    For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

    Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.

    Please also refer to the ICMJE Recommendations for the Protection of Research Participants.

    4.7 Clinical trials

    Nanobiomedicine conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.

    4.8 Reporting guidelines

    The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.

    Back to top

    5. Publishing policies

    5.1 Publication ethics

    SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.

    5.1.1 Plagiarism

    Nanobiomedicine and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

    5.1.2 Prior publication

    If material has been previously published, it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.

    5.2 Contributor's publishing agreement

    Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement.  Nanobiomedicine publishes manuscripts under Creative Commons licenses. The standard  license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page.

    Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.

    Back to top

    6. Preparing your manuscript

    6.1 Word processing formats

    The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.

    6.2 Artwork, figures and other graphics

    For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines.  

    Figures supplied in colour will appear in colour online.

    6.3 Supplementary material

    This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files.

    6.4 Reference style

    Nanobiomedicine adheres to the SAGE Vancouver reference style. Please review the guidelines on SAGE Vancouver to ensure your manuscript conforms to this reference style.

    If you use EndNote to manage references, you can download the SAGE Vancouver output file here.

    6.5 English language editing services

    Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.

    Back to top

    7. Submitting your manuscript

    Nanobiomedicine is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/Nanobiomedicine to login and submit your article online.

    IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created.  For further guidance on submitting your manuscript online please visit ScholarOne Online Help.

    7.1 ORCID

    As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a persistent digital identifier that distinguishes researchers from every other researcher and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities ensuring that their work is recognised.

    We encourage all authors to add their ORCIDs to their SAGE Track accounts and include their ORCIDs as part of the submission process. If you don’t already have one you can create one here.

    7.2 Informtion required for completing your submission

    You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).

    7.3 Corresponding author contact details

    Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.

    7.4 Permissions

    Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway

    Back to top

    8. On acceptance and publication

    If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been check for SAGE Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days.

    8.1 SAGE Production

    Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly.  Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change.

    8.2 Online publication

    One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.

    8.3 Promoting your article

    Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximise your article’s impact with Kudos

    Back to top

    9. Further information

    Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Nanobiomedicine editorial office as follows:

    nbm@sagepub.co.uk

    Back to top